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Abstract
Background: While multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are primarily inflammatory and
degenerative disorders respectively, there is increasing evidence for shared cellular mechanisms that may affect disease
progression, particularly glial responses. Cyclooxygenase 2 (COX-2) inhibition prolongs survival and cannabinoids
ameliorate progression of clinical disease in animal models of ALS and MS respectively, but the mechanism is uncertain.
Therefore, three key molecules known to be expressed in activated microglial cells/macrophages, COX-2, CB2 and
P2X7, which plays a role in inflammatory cascades, were studied in MS and ALS post-mortem human spinal cord.
Methods: Frozen human post mortem spinal cord specimens, controls (n = 12), ALS (n = 9) and MS (n = 19), were
available for study by immunocytochemistry and Western blotting, using specific antibodies to COX-2, CB2 and P2X7,
and markers of microglial cells/macrophages (CD 68, ferritin). In addition, autoradiography for peripheral benzodiazepine
binding sites was performed on some spinal cord sections using [3H] (R)-PK11195, a marker of activated microglial cells/
macrophages. Results of immunostaining and Western blotting were quantified by computerized image and optical
density analysis respectively.
Results: In control spinal cord, few small microglial cells/macrophages-like COX-2-immunoreactive cells, mostly bipolar
with short processes, were scattered throughout the tissue, whilst MS and ALS specimens had significantly greater
density of such cells with longer processes in affected regions, by image analysis. Inflammatory cell marker CD68-
immunoreactivity, [3H] (R)-PK11195 autoradiography, and double-staining against ferritin confirmed increased
production of COX-2 by activated microglial cells/macrophages. An expected 70-kDa band was seen by Western blotting
which was significantly increased in MS spinal cord. There was good correlation between the COX-2 immunostaining
and optical density of the COX-2 70-kDa band in the MS group (r = 0.89, P = 0.0011, n = 10). MS and ALS specimens
also had significantly greater density of P2X7 and CB2-immunoreactive microglial cells/macrophages in affected regions.
Conclusion: It is hypothesized that the known increase of lesion-associated extracellular ATP contributes via P2X7
activation to release IL-1 beta which in turn induces COX-2 and downstream pathogenic mediators. Selective CNS-
penetrant COX-2 and P2X7 inhibitors and CB2 specific agonists deserve evaluation in the progression of MS and ALS.
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Background
Multiple sclerosis (MS) is a chronic, immune-mediated
disorder of the central nervous system. MS patients may
be affected by a relapsing-remitting form of the disease,
but a large proportion of patients will progress to a sec-
ondary progressive form of the disease, which results in a
gradual and progressive loss of neurological function.
Progression of neurological dysfunction is also a charac-
teristic of amyotrophic lateral sclerosis (ALS), a neuro-
degenerative motor disorder with poor prognosis. While
new treatments have shown some efficacy in ALS and MS
[1,2], more effective therapies are required to slow pro-
gression and reduce disability and mortality. As there is
increasing evidence for shared cellular mechanisms that
may affect disease progression in CNS disorders, particu-
larly glial responses, we have studied the expression of key
mechanisms in the neuro-inflammatory cascade, COX-2,
CB2 and P2X7, in MS and ALS post-mortem human spinal
cord.
There are two major forms of cyclooxygenase (COX), the
iso-enzymes, COX-1 and COX-2 [3]. COX-1 is constitu-
tively synthesized in a variety of tissues including gastric
mucosa, liver, kidneys, and platelets where, prostaglandin
production in these sites maintains normal tissue func-
tion. COX-2 is an inducible enzyme that is present in low
amounts in normal adult tissues but is increased in
peripheral and central nervous system and in monocytes
following injury or inflammation [4]. Gene targeting tech-
niques have been used to create strains of "knockout"
mice that lack COX-2. These strains have frequent repro-
ductive failures, kidney dysfunction, and a shortened life
span [5]. Reproductive failure appears related to specific
COX-2-, but not COX-1-derived prostaglandin that is
essential for placental formation and maintenance [5].
Carrageenan induces inflammation in COX-2-deficient
mice, and these inflammatory responses can be sup-
pressed in part by COX-1 inhibition, suggesting that COX-
1 may also mediate inflammation in these animals.
COX-2 expression is increased by a number of pro-inflam-
matory cytokines, including interleukin 1 and tumor
necrosis factor alpha, as well as by other factors, including
endotoxin, hypoxia, ischemia, epidermal growth factor
and transforming growth factor beta 1. COX-2 expression
is increased in spinal cord neurons following peripheral
inflammation [6]. Inflammation produces robust
increases in COX-2 expression diffusely in the rat brain,
especially in and around blood vessels. Prostaglandins
derived from COX-2 expression in cerebral vessels appear
important in the generation of fever. Focal or global cere-
bral ischemia dramatically induces COX-2 expression [7].
Inhibition of both COX-1 and COX-2 may contribute to
spinal analgesic and anti-hyperalgesic actions of non-ster-
oidal anti-inflammatory drugs [8]. COX-2 inhibitors have
also recently been suggested [9] as possible alternatives to
glucocorticoids in the treatment of peritumoral edema in
patients with malignant brain tumours, as they showed
that glioma-infiltrating microglia are a major source of
PGE2 production through the COX-2 pathway.
Recently, COX-2 mRNA was shown to be up-regulated in
ALS spinal cord [10,11]. COX-2 inhibitors have been
shown to have a therapeutic role in a transgenic mouse
model of ALS [12]. These authors showed that prophylac-
tic administration of the preferential COX-2 inhibitor,
nimesulide, in the feed resulted in a significant delay in
the onset of ALS type motor impairment.
Marijuana has been used for at least 4000 years as both a
therapeutic agent and a recreational drug and the psycho-
active ingredient is ∆9-tetrahydrocannabinol (THC). It is
known that THC binds to receptors in the CNS known as
CB1 and that a second subtype of these receptors CB2 are
mainly present in the periphery in the normal state, par-
ticularly on macrophage cells of the immune system [13].
Actions of cannabinoids at peripheral cannabinoid recep-
tors may explain altered immune function after long-term
cannabinoid administration. Cannabinoids acting at CB2
receptors in the immune system cause inhibition of T-cell-
dependent humoral immune responses through direct
inhibition of accessory T-cell function [14]. Anandamide
(arachidonoylethanolamide, AEA) and 2-arachidonoylg-
lycerol (2-AG) are endogenous ligands of cannabinoid
receptors [15]. The endocannabinoid system (the cannab-
Table 1: Antibodies used in this study
Antibody Donor Source Ref Dilution
Mouse COX-2 Mouse BD Biosciences, Oxford UK. C22420 1/750
Mouse P2X7 Mouse Geneva Biomedical Research Institute EL101116/122 L4 1/4000
Ferritin Rabbit Abcam, Cambs. UK Ab7332 1/1000
CD2 Mouse Dako, High Wycombe, UK M0720 1/100
CD68 Mouse Dako, High Wycombe, UK EBM11 1:500
CB2 Rabbit GSK, Harlow, UK GST-CB2C 1:200
Human CB2 Goat Santa Cruz C-15, sc-10073 1.4000
Human CB2 Rabbit Santa Cruz H-60, sc-25494 1:500BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
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inoid receptors and their endogenous ligands) seems to
play a role in neuroprotection, as suggested by the up-reg-
ulation of CB1 receptor expression and the elevated con-
centrations of endocannabinoids in some in vivo models
of neurodegeneration and brain injury [16]. Recent find-
ings have shown that cannabinoids can down-regulate the
production of nitric oxide (NO), in macrophages [17] and
also in rat microglial and glial cells. Activated glial cells
have also been proposed to play an active role in many
neurodegenerative pathologies including MS and ALS
[18,19] through the production and release of several pro-
inflammatory and cytotoxic mediators including nitric
oxide.
P2X7 is the most recently cloned member of the ATP-acti-
vated ligand-gated ion channel superfamily [20], and has
been shown to cause externalisation of mature, biologi-
cally active IL-1β [21]. In addition, ATP is able to act in an
autocrine manner when released from cells challenged by
inflammatory initiators (e.g. LPS, [22], where P2X7 antag-
onists impair release of IL1β in mice lacking the P2X7
gene, release of mature IL-1β in response to LPS and ATP
is absent [23]. Release of IL-1β leads to up-regulation of
gene products which contribute to the inflammatory state,
including matrix metalloproteinase's, COX-2, inter-
leukins, and cellular adhesion molecules [24]. This piv-
otal role of the P2X7 receptor in the inflammatory cascade
is hypothesised to be triggered by release of ATP from cells
undergoing apoptosis or necrosis in neurodegenerative
and neuroinflammatory processes, as it is well established
that even mild perturbation of cells can cause ATP release
[25]. The predominant expression of P2X7 is thought to be
in immune cells including macrophages and microglial
cells/macrophages [26], candidate cell populations for
contribution to neurodegeneration observed in MS and
ALS. Thus, it may be hypothesized that persistent activa-
tion of P2X7 may play a role in the pathogenesis of these
neurodegenerative conditions.
In this study we show, by using immunochemical meth-
ods, that COX-2, CB2 and P2X7 immunoreactivity are
localised mainly in activated microglial cells/macro-
phages in ALS and also MS cord, and that it is co-localised
with the microglial cell/macrophage markers CD68, [26],
and ferritin [27]. In addition, 3 [H] PK11195 autoradio-
graphic binding studies [28] has been used to further cor-
roborate regions of microglial cell/macrophage
activation, in comparison with the above markers.
Methods
Spinal cord
Segments of deep frozen human spinal cord were
obtained from the rapid autopsy system of the Nether-
lands Brain Bank (NBB) and MRC Brain Bank, King's Col-
lege London, from a total pool of controls (n = 12), ALS
(n = 9) and MS (n = 19), for study by immunocytochem-
istry, Western blotting and autoradiography for peripheral
benzodiazepine binding sites. All MS tissues were classi-
fied according to the following criteria: 1. preactive lesions
– expression of CD68, CD 45 on clusters of perivascular
microglial cells in white matter with no loss of myelin, 2.
active demyelinating lesions, characterized by the pres-
ence of macrophages with luxol fast blue or myelin basic
protein (MBP) – positive inclusions, and GFAP-positive
reactive astrocytes with long processes, in demyelinating
regions 3. Chronic active – hypocellular demyelinated
centre of the lesions containing a small number of CD 68-
postive macrophages, with reactive astrocytes localized
mainly at the edge of the lesion, or 4. Chronic non-active
lesions – hypocellular demyelinated lesion with gliosis
(as described previously, validated by MRI-guided sam-
pling) [29,30]. ALS lumbar spinal cord was obtained post-
mortem from patients with clinically and pathologically
confirmed sporadic ALS (Mean disease duration was 34
months, ranging from 7–84 months; mean age 67 years,
range 51–76 years). The post-mortem delay for ALS
patients ranged from 4 to 24 h, and for control subjects
from 14 to 26 h.
Immunocytochemistry
Frozen, transverse sections (12 µm) of spinal cord were
collected onto poly- L – lysine coated slides and post-fixed
in freshly prepared, 4% w/v paraformaldehyde in PBS for
30 min. Sections were then dehydrated through graded
alcohols and endogenous peroxidase blocked by incuba-
tion with 0.3% w/v hydrogen peroxide for 30 min. After
re-hydration and washing in PBS, sections were incubated
overnight with primary antibody (Table 1). Sites of pri-
Microglial cells/macrophages in control spinal cord immunos- tained with antibodies to A) COX-2, B) CB2, C) P2X7, and  D) CD68 Figure 1
Microglial cells/macrophages in control spinal cord immunos-
tained with antibodies to A) COX-2, B) CB2, C) P2X7, and 
D) CD68. Scale bar = 50 µm.BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
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mary antibody attachment were revealed using avidin-
biotin peroxidase method (Vector Labs UK – ABC – black
product) and nuclei were counterstained in 0.1% w/v
Neutral Red to give contrasting pink/red nuclei but not in
double labelling experiments to avoid confusing colours.
For CB2 specificity studies, experiments were performed
with the primary antibody (Santa Cruz S-16 only, at a titre
of 4 K) incubated with antigenic peptide (20, 2 and 0.2
µg/ml) for 2 hours prior to incubation with the sections.
Peptide was not available for specificity studies for COX-2
and P2X7, but other methodological controls were per-
formed (omission of primary antibodies, sequential dilu-
tion of antibodies).
Co-localisation studies
In order to further characterise cells with P2X7 or COX-2
immunoreactivity, serial sections were double labelled by
incubation with a mixture of primary antibodies of either
COX-2 and Ferritin or P2X7 and Ferritin. Immunoreac-
tions for COX-2 and P2X7 were revealed using alkaline
phosphatase (APAAP – DAKO Ltd) to give a red product,
whilst Ferritin immunoreactivity was revealed using the
nickel-enhanced ABC peroxidase method to give a grey/
black product. Double-labelled preparations were air
dried without counterstaining and mounted in Vecta-
mount medium (Vector Labs UK).
Image analysis
To quantify immunoreactivity of the various markers,
computerized image analysis was performed (SeeScan
Cambridge, UK). Images were captured via video link to
an Olympus BX50 microscope at × 40 objective magnifi-
cation so that tissue fully occupied each field, and scanned
by the computer. Positive immunostaining was high-
lighted by setting the grey-level detection limits to thresh-
old and the area of highlighted immunoreactivity
COX-2 immunoreactivity in MS spinal cord is in microglial cells/macrophages Figure 2
COX-2 immunoreactivity in MS spinal cord is in microglial cells/macrophages. (A) Autoradiographic localisation of 3 [H] 
PK11195 in a spinal cord from a patient with MS, co-located with CD68 (D) (Scale bars = 1000 µm). The square indicates the 
area where subsequent CD68 and COX-2 images were taken from. B) And E) Microglial cell/macrophage-like immunostaining 
with CD68 antibody (Scale bars = 200 µm and 100 µm respectively). C) And F) Microglial cell/macrophage-like immunostaining 
with COX-2 (Scale bars = 200 µm and 100 µm respectively).BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
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obtained as % area of the field scanned. Five fields per tis-
sue section were scanned and the mean value used in sub-
sequent statistical analysis.
Western blot studies
Spinal cord from 6 control and 7 MS patients was availa-
ble for Western blotting. Spinal cord extracts and mouse
macrophage control extracts (BD Biosciences, Oxford,
UK) were processed for Western blotting as described
[31]. To ensure that similar amounts of protein were
loaded onto gels, protein extracts (20 µg; measured by the
Bradford dye-binding protein assay, Bio-Rad laboratories,
Hertfordshire, UK) were loaded and protein bands visual-
ised by staining membranes with 0.1% (w/v) Ponceau S in
1% (v/v) acetic acid. Only lanes that had similar protein
profiles were used for subsequent Western blot analysis.
Positive control for the Western blots was mouse macro-
phage (BD Biosciences, Oxford, UK) extract which also
reacted to give a strong 70 kDa band. The COX-2 antibody
was used at a titre of 1:2,000. Optical density readings of
autoradiographs were taken using a Digit-X densitometer
(X-Ograph Ltd, Wiltshire, UK) evenly illuminated on a
photography viewer. Background readings were deter-
mined by measuring optical density outside the sample
lanes. After subtraction of background, the mean of three
consecutive readings of protein immunoreactivity at the
70-kDa positions for each sample lane was obtained.
Comparisons of control with MS spinal cord specimens
were performed on separate occasions using the same
original extracts. Because of inter-gel variation, only gels
that were performed on the same day were used in com-
parison studies. Inter-gel variation was corrected by com-
paring the optical density of the positive control in each
blot and adjusting the optical density readings accord-
ingly. This was less than 10%. Because of loading limita-
tions due to the number of wells on the comb it was
necessary to perform Western blots on more than one
occasion in order to increase number of patient extracts
for statistical validity. Our results and controls were repro-
ducible on each occasion. Data was analysed using Mann
Whitney U test using GraphPad Prism software, P < 0.05
indicated significance.
PK11195 binding studies
Autoradiography [32] was performed on unfixed cryostat
sections of snap-frozen CNS tissue from human post-
mortem material using custom synthesised single enanti-
omer [3H] R-PK11195 (Amersham, UK) which in previ-
ous studies has been shown to possess higher affinity for
the peripheral benzodiazepine binding sites than the
commonly used racemate of PK11195 [33].
CB2 staining in MS and ALS spinal cord is in microglial cells/ macrophages Figure 4
CB2 staining in MS and ALS spinal cord is in microglial cells/
macrophages. A) CB2 staining in MS spinal cord. Inset: CB2 
staining in parenchymal microglial cells/macrophages. (Scale 
bar = 50 µm). B) Microglia-like immunostaining with CD68 in 
the same area as in A (Scale bar = 50 µm). C and D) CB2 
staining in ALS spinal cord (Scale bar = 500 µm and 50 µm, 
respectively). E and F) Microglia-like immunostaining with 
CD68 (Scale bar = 500 µm and 50 µm, respectively).
COX-2 immunoreactivity is increased significantly in MS spi- nal cord Figure 3
COX-2 immunoreactivity is increased significantly in MS spi-
nal cord. A horizontal line indicates the median value from 
each group. * P = 0.025BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
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CB2-immunoreactivity is increased in MS and ALS spinal cords Figure 5
CB2-immunoreactivity is increased in MS and ALS spinal cords. A) Mean % area of CB2 in spinal cord taken from MS (with and 
without lesion, filled squares and circles respectively) and control spinal cord (open circles) using computerized image analysis. 
A horizontal line indicates the median value from each group. B) Mean % area of CB2 in ALS spinal cord and CD68 immunore-
activity taken from control and ALS spinal cord using computerized image analysis. A horizontal line indicates the median value 
from each group, WM, white matter; VH, ventral horn; DC, dorsal column; NAWM, non affected white matter.
Results
Control spinal cord
Antibodies to COX-2, CB2 and P2X7 were immunoreac-
tive with scattered, small, nucleated cells some showing
fine short processes typical of microglial cells/macro-
phages (Fig 1A – C). Similar staining was obtained with
antibodies to CD68 (Fig. 1D) which is known to be a
marker of microglial cells/macrophages.
Multiple Sclerosis
Autoradiography
Regional increases of PK11195 binding were found in MS
plaques and associated white matter tracts (Fig 2A), and
closely matched the spatial distribution of activated
microglial cells/macrophages immunostained by CD68
antibodies.BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
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Immunocytochemistry
CD68
Strong microglial cell/macrophage-like staining was seen
in affected regions with the antibody to CD68; cells were
bipolar with long processes (Fig 2B, 2D and 2E) in both
sets of spinal cord specimens. There was no overall differ-
ence between the groups: Control spinal cord, n = 7, %
area, median and range, 3.54 (2.79–4.99), MS spinal
cord, n = 10, 3.92 (2.51–6.68), P = 0.6.
COX-2
All samples showed glial-like cells, mostly bipolar with
short processes scattered throughout the tissue. The proc-
esses appeared longer in MS spinal cord, which also
appeared to have a greater density of glial-like cells, partic-
ularly around plaques (Fig 2C and 2F) and was confirmed
by image analysis (Fig 3).
CB2
Weak CB2 -immunoreactivity was detected in control spi-
nal cord as, small, glial/ macrophage-like cells with no
processes, which were scattered throughout the tissue,
whilst MS specimens with lesions had a greater density of
such glial-like cells, observed with both CB2 antibodies.
These were more frequent in the white matter in MS sec-
tions with lesions, appeared in clusters, usually in or on
the edge of areas of plaques (Fig 4A). CB2 staining in MS
spinal cord specimens with no apparent lesions appeared
similar to control cord. CB2 staining (Santa Cruz anti-
body, C-15, sc-10073) in specimens with lesions was
increased significantly as measured by image analysis (P =
0.0003; Fig 5A). This immunoreactivity was completely
abolished when antibody was pre-absorbed with corre-
sponding peptide (available for Santa Cruz antibody
only).
Strong microglial cell/macrophage-like staining was seen
with the antibody to CD68; cells were bipolar with long
processes in both sets of spinal cord specimens (Fig 4B).
There was no difference between the control and MS spec-
imens with no apparent lesions: control spinal cord, n =
8, % area, median and range, 2.979 (1.934–3.824), MS
spinal cord no lesion, n = 18, 4.155 (2.46–11.74), P =
0.0628. However, there was a difference in the MS cord
with lesions 12.67 (8.88–15.75), P = 0.012 compared to
controls.
Western blotting
A 70 kDa COX-2 band was observed in mouse macro-
phage control and human spinal cord extracts, which was
clearly more prominent in the MS spinal cords (Fig 6).
There was good correlation between the COX-2 % area
and the optical density of the COX-2 70-kDa band
obtained previously in the MS group, Spearman r = 0.89,
COX-2 Western blots correlate with immunohistochemistry  studies Figure 7
COX-2 Western blots correlate with immunohistochemistry 
studies. Spearman plots of COX-2, 70 kDa optical density 
readings compared to COX-2 image analysis from MS spinal 
cords. Number of XY pairs 10.
Top panel, representative Western blots of the COX-2 70  kDa band in control (lanes 1–6) and MS (lanes 7 – 11), and  lane 12 mouse macrophage positive control Figure 6
Top panel, representative Western blots of the COX-2 70 
kDa band in control (lanes 1–6) and MS (lanes 7 – 11), and 
lane 12 mouse macrophage positive control. Bottom panel, 
optical density analysis of COX-2 Western blots. Relative 
optical density readings of COX-2, 70-kDa bands in the spi-
nal cord of controls compared to MS specimens.BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
Page 8 of 14
(page number not for citation purposes)
P = 0.0011 (Fig 7). There was no significant correlation
between the COX-2 readings in the control spinal cord
group, n = 7, Spearman r = -0.3152, P = 0.5.
P2X7
P2X7 immunoreactivity was detected mostly in white mat-
ter in cells having the appearance of microglial cells/mac-
rophages (Fig 8C and 8F). Immunoreactivity in
macrophages was strongest at the cell surface membrane.
Immunostaining of serial sections with antibodies to the
macrophage marker CD68 (Fig 8B, 8D, 8E) showed very
similar staining patterns. MS cases showed P2X7-immu-
noreactive macrophages in clumps/plaques with an accu-
mulation of cells in and around blood vessels. There was
a significant (P = 0.032) increase of P2X7 -immunostain-
ing in MS cords (Fig 9).
Co-localisation studies
Immunostaining with a mixture of antibodies to ferritin
and COX-2 or P2X7 showed that the majority of cells with
red (P2X7 – Fig 10A; COX-2 – Fig 10B) immunoproduct
also contained black immunoproduct (ferritin), indicat-
ing the presence of P2X7 and/or COX-2 in microglial cells/
macrophages.
Amyotrophic lateral sclerosis
Autoradiography
Regional increases of 3 [H] PK11195 binding were found
along the corticospinal tract region and closely matched
the distribution of activated microglial cells/macrophages
immunostained by CD68 antibodies (Fig 11A, B, D, E).
Immunocytochemistry
COX-2
All samples showed glial-like cells, mostly bipolar with
short processes scattered throughout the tissue. The proc-
P2X7 immunoreactivity is found in microglial cells/macrophages of MS spinal cord Figure 8
P2X7 immunoreactivity is found in microglial cells/macrophages of MS spinal cord. (A) Autoradiographic localisation of 3 [H] 
PK11195 in a spinal cord from a patient with MS co-located with CD68 (D) (Scale bars = 1000 µm). The square indicates the 
area where subsequent CD68 and P2X7 images were taken from. B) And E) Microglial cells/macrophage -like immunostaining 
with CD68 antibody (Scale bars = 200 µm and 100 µm respectively). C) And F) Microglial cells/macrophage -like immunostain-
ing with P2X7 (Scale bars = 200 µm and 100 µm respectively).BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
Page 9 of 14
(page number not for citation purposes)
ess appeared slightly longer in ALS spinal cord (but not as
long as MS cord) and also appeared to have greater den-
sity of glial-like cells compared to controls (Fig 11C, 11F).
This was confirmed in dorsolateral white matter but not in
the grey matter or dorsal columns by image analysis (Fig
12, top). In contrast there was no difference between these
regions in control cord.
CB2
In all amyotrophic lateral sclerosis cord very intense CB2
microglial cell/macrophage-like staining, associated with
long processes, was localized in the dorsolateral white
matter, in the region of the degenerating corticospinal
tracts (Fig 4C and 4D). Image analysis of these lesions in
ALS cords, using the GSK antibody, showed a significant
increase of CB2 compared to the dorsolateral white matter
of controls (P = 0.0104), and within both the dorsal col-
umns (P = 0.0011) and grey matter (P = 0.0059) of ALS
cords (Fig 5B). In contrast there was no difference
between these regions in control cord. Similar staining of
CB2 in activated microglial cells/macrophages in ALS cord
was also observed with the Santa Cruz antibody H-60, sc-
25494 (data not shown).
CD68
In all ALS cord very intense microglial cell/macrophage-
like staining associated with long processes were seen with
the antibody to CD68 at a titre of 1:750. Staining was
almost exclusively localized to the dorsolateral white mat-
ter (Fig 8D and 11D) and significantly increased com-
pared to grey matter in ALS (P = 0.0022) and dorsolateral
white matter of controls (P = 0.0012) using image analysis
(Figure 12, bottom).
P2X7
All ALS cases showed large numbers of P2X7-immunore-
active microglial cell/macrophage-like cells particularly in
the dorsolateral white matter and in some cases in ante-
rior columns (Fig 13C, 13F – P2X7; Fig 13B, 13E – CD68).
These cells were significantly increased in the white matter
of ALS cord P = 0.0001 (Fig 14). In most cases of control
spinal cord only occasional, P2X7-immunoreactive mac-
rophages were detected in contrast to diseased spinal cord
that showed cells in abundance. There was relatively neg-
ligible P2X7-immunoreactivity in the grey matter from
either control or ALS cord. Double labelling with antibod-
ies to the microglial cell/macrophage marker, Ferritin
showed P2X7 and COX-2 present in microglial cells/mac-
rophages (Fig 15A – COX-2/ferritin; 15B – P2X7/ferritin).
Discussion
The studies reported here demonstrate that MS spinal cord
contained increased levels of COX-2, CB2 and P2X7 recep-
tor in affected regions compared to control spinal cords.
The immunohistochemical studies showed a greater
number of microglial cells/macrophages containing COX-
2 and CB2 immunoreactivity in MS compared to control
spinal cord. In MS cord, both COX-2 and CB2 -immuno-
reactive microglial cells/macrophages often had long
processes, particularly when located within active
plaques.
In ALS spinal cord, COX-2 was also elevated in regions
known to be affected in this condition when compared to
control spinal cord, as previously reported [11]. However,
in our study, we find the increased COX-2 in microglial
cells/macrophages, and not in grey matter or neurons. The
increased COX-2-immunoreactive microglial cells/macro-
phages were localized in the affected regions of the spinal
cord, such as dorsolateral white matter with corticospinal
tract degeneration, and not in the dorsal columns, which
Co-localisation studies of COX-2 and P2X7 in MS spinal cord Figure 10
Co-localisation studies of COX-2 and P2X7 in MS spinal 
cord. Double staining of COX-2 or P2X7 cells with the 
microglia marker ferritin in MS spinal cord. Sections were 
incubated with mixture of A) Ferritin (black) and COX-2 
(red) antibodies or B) ferritin (black) and P2X7 (red). The 
majority of COX-2 or P2X7 immunoreactive cells appear to 
be microglial cells/macrophages. Scale bar = 100 µm. P2X7 immunoreactivity is increased in MS spinal cord Figure 9
P2X7 immunoreactivity is increased in MS spinal cord. Mean 
% area of P2X7 immunoreactivity taken from control and MS 
spinal cord using computerized image analysis. A horizontal 
line indicates the median value for each group.BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
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are spared in this condition. In other studies Cox-2 mRNA
and protein were found to be significantly elevated in ALS
cord, but the location of this increase was not reported
[10]. COX-2 over-expression in the spinal cord of patients
with ALS has also been shown to be present in neurons
and glial cells of the CNS [34] and some reports have
shown that COX-2 immunoreactivity in normal rats is
localised to neurons of laminae II-III, motoneurons of
lamina IX and glial cells [6,35]. In support of this we have
found COX-2 immunoreactivity in our studies of human
and rat peripheral nerves using the same methods and
antibodies as the present study [36]. We did not detect
neuronal associated COX-2 immunoreactivity in any of
the spinal cord specimens studied including the control
spinal cords, in which only a few microglial cells/macro-
phages with few processes were COX-2 -immunoreactive.
These contrasting results between laboratories may reflect
differences in methods and/or reagents. In rats, induction
of COX-2 mRNA expression in the spinal cord has been
demonstrated after intraspinal injections of IL-1α [37] or
after mechanical injury to the spinal cord [38]. COX-2
immunoreactivity was also found in vascular endothelial
cells and glial cells after IL-1α challenges [37].
Glial activation, including microglial cells/macrophages,
is a major histopathological feature of MS and ALS, and
may reflect the severity of the disease process. The precise
mechanisms of glial activation in these diseases are not
fully understood; recent observations implicate a puriner-
gic-signaling pathway [39]. Our findings show that P2X7
is up regulated in activated microglial cells/macrophages.
A cascade may be postulated – cell death raises extracellu-
lar ATP [40], which activates P2X7 expressed by microglial
cells/macrophages; the latter release IL1β, which in turn
induces COX-2. IL1β and PGE2 lead to further cell death
and ATP release, and the cycle is perpetuated. In addition,
recent reports suggest that ATP, as well as activating quies-
cent microglial cells/macrophages [41], is able to act as a
chemoattractant for microglial cells/macrophages [42],
directing them to the source of injury. This, coupled with
COX-2 immunoreactivity in ALS spinal cord found in microglial cells/macrophages predominantly in white matter Figure 11
COX-2 immunoreactivity in ALS spinal cord found in microglial cells/macrophages predominantly in white matter. (A) Autora-
diographic localisation of 3 [H] PK11195 in a spinal cord from a patient with ALS co-located with CD68 (D) (Scale bars = 1000 
µm). The square indicates the area where subsequent CD68 and COX-2 images were taken from. B) And E) Microglial cells/
macrophage -like immunostaining with CD68 antibody (Scale bars = 200 µm and 100 µm respectively). C) And F) Microglial 
cells/macrophage-like immunostaining with COX-2 (Scale bars = 200 µm and 100 µm respectively).BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
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the release of superoxide from microglial cells/macro-
phages following P2X7 ligation [43] suggests a pivotal role
of microglial cells/macrophages in the degenerative proc-
esses associated with these diseases. While constitutive
expression of P2X7 and COX-2 have been reported in dif-
ferent cell types in the brain [6], our data suggest that
increased expression of these molecules in MS and ALS
occurs predominantly within activated microglial cells/
macrophages. In accord with the acknowledged role of
microglial cells/macrophages as the brain's endogenous
immune effector cells, their presence in inflammatory and
degenerative processes may underlie the commonality of
pathological mechanisms, which may be targeted to mod-
ify disease progression, irrespective of the primary cause.
It has been shown recently that peripheral benzodi-
azepine receptor ligand PK11195 inhibits the lipopolysac-
charide-induced COX-2 expression in human microglial
cells/macrophages [44]. This suggests that the binding of
this ligand to the PBR site on the mitochondrial outer
membrane of microglial cells/macrophages could serve
an anti-inflammatory function in the CNS. Thus, the
development of drugs that can bind the mitochondrial
outer membrane of microglial cells/macrophages, or even
the peripheral benzodiazepine receptor ligand PK11195
itself, may be of use in the treatment of some patients with
MS and/or ALS. Inhibition of COX-2 has indeed been
shown to prevent or attenuate disease progression, in an
ALS animal model [12].
The finding of CB2 in microglial cells/macrophages in
human spinal cord is of interest as cannabinoids have
been shown in animal models to regulate microglial cell/
macrophage cell migration [45]. These authors demon-
strated a cannabinoid signalling system involving recruit-
ing microglial cells/macrophages towards dying neurons.
Of particular interest to the present study, they demon-
strated that activated microglial cells/macrophages
expressed CB2 receptors at the leading edge of lamellipo-
dia, consistent with the involvement of microglial cells/
macrophages in cell migration. Various synthetic cannab-
inoids have been shown to suppress experimental
autoimmune encephalomyelitis (EAE, an animal model
of MS) by suppressing inflammation in brain and spinal
cord of treated animals [46], including amelioration of
both tremor and spasticity in diseased mice [47]. Suppres-
sion of EAE by cannabinoids may be related to their effect
on corticosterone secretion [48].
Chronic pain models (CCI or Bennett and Chung models,
sciatic nerve and spinal nerve ligation, respectively) asso-
ciated with peripheral nerve injury but not inflammatory
chronic pain models (Freund's complete adjuvant injec-
tion in the paw) have been shown to induce CB2 mRNA
expression in rat lumbar spinal cord on activated micro-
glial cells/macrophages, in regions undergoing neuronal
damage [49]. Treatment of rats infected with Theiler's
virus (a murine model of multiple sclerosis), with the syn-
thetic cannabinoids WIN 55,212-2, ACEA and JWH-015
during established disease significantly improved the neu-
rological deficits of this disease and reduced microglial
cell/macrophage activation in the spinal cord [50,51].
Recently, the selective CB2 receptor agonist AM1241 was
shown to reverse tactile and thermal hypersensitivity pro-
duced by ligation of the L5 and L6 spinal nerves in rats
[52]. This agonist also blocked spinal nerve ligation-
induced tactile and thermal hypersensitivity in CB1
knock-out mice, suggesting a mechanism leading to the
inhibition of pain that targets receptors outside the CNS.
Recently, in CB1 knock out-mice with acute EAE had more
prolonged calcium fluxes induced by NMDA agonists and
kanic acid induced seizures and death occurred at much
lower doses in these animals [53] compared to controls.
This suggests that cannabinoids may reduce the excito-
toxic effects of acute inflammation on axons. Cannabi-
COX-2 is increased in the dorsolateral white matter of ALS  spinal cord Figure 12
COX-2 is increased in the dorsolateral white matter of ALS 
spinal cord. Top, Mean % area of COX-2 immunoreactivity in 
spinal cord (open box, control, shaded ALS) and bottom, 
Mean % area of CD68 immunoreactivity in spinal cord. Mean 
± SEM * P = 0.0012, ** P = 0.0047.BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
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noids are predicted not to alter relapse frequency but to
reduce the disability acquired as a result of each relapse
often seen in MS.
In rats, local administration of the selective CB2 agonist
JWH-133 induced a significant regression of malignant
tumours generated by inoculation of C6 glioma cells. Evi-
dence of the involvement of CB2 demonstrated, included,
the prevention by CB2 but not CB1 antagonists and
down-regulation of the CB2 receptor but not CB1 in the
tumours themselves. Selective CB2 agonists also induced
a considerable growth inhibition on both malignant
tumours and tumour vascularization, generated by inocu-
lation of epidermal tumour cells into mice.
CB2 cannabinoid specific agonists have a spectrum of
effects that make them very promising candidates for the
treatment of pain and, in view of our findings, CNS
inflammation and neurodegeneration. In preclinical stud-
ies, they inhibit signs of acute nociceptive, inflammatory
and neuropathic pain. Because of their peripheral distri-
bution they are predicted not to cause the CNS effects
associated with CB1 agonists in normal subjects [54]. Fur-
thermore, it may be possible to up-regulate endogenously
produced cannabinoids such as anandamide and 2-AG to
mediate therapeutic benefit.
Conclusion
We conclude that selective CNS-penetrant COX-2 and
P2X7 inhibitors and CB2 agonist deserve evaluation in the
progression of MS and ALS.
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P2X7 immunoreactivity localised to microglial cell/macrophage-like cells in ALS spinal cord Figure 13
P2X7 immunoreactivity localised to microglial cell/macrophage-like cells in ALS spinal cord. (A) Autoradiographic localisation of 
3 [H] PK11195 in a spinal cord from a patient with ALS co-located with CD68 (D) (Scale bars = 1000 µm). The square indicates 
the area where subsequent CD68 and P2X7 images were taken from. B) And E) Microglial-like immunostaining with CD68 anti-
body (Scale bars = 200 µm and 100 µm respectively). C) And F) microglial cell/macrophage-like immunostaining with P2X7 
(Scale bars = 200 µm and 100 µm respectively).BMC Neurology 2006, 6:12 http://www.biomedcentral.com/1471-2377/6/12
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